Author’s response to reviews

Title: BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score

Authors:

Mark Zarella (mark.zarella@drexelmed.edu)
Rebecca Heintzelman (rebecca.heintzelman@ctca-hope.com)
Nikolay Popnikolov (nikolay.popnikolov@drexelmed.edu)
Fernando Garcia (fernando.garcia@ctca-hope.com)

Version: 1 Date: 07 Aug 2018

Author’s response to reviews:

We thank Dr. Turner for his review and his helpful suggestion. We have edited the Results section of the manuscript to more clearly state the results of the experiments while eliminating excess discussion of the methodology. We have removed redundancy between the Results and Methods section, and have moved some of the commentary that was previously in the Results section into the Discussion section. In addition, we added a sentence to the end of the Results section (line 259) to address the new results from the TAILORx trial that were recently published in JAMA to more clearly support our contention that cases near the boundary of low- and intermediate-risk are unlikely to benefit from chemotherapy. This sentence replaces a more cumbersome paragraph describing chemotherapy benefit.